Nonalcoholic Fatty Liver Disease

In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.

SAN DIEGO — Patients with rheumatoid arthritis who receive hydroxychloroquine demonstrate a lower risk for nonalcoholic fatty liver disease, according to data presented at ACR Convergence 2023.

BOSTON — An intensive, advanced practice provider-guided weight loss program helped patients with metabolic dysfunction-associated steatotic liver disease achieve statistically significant weight loss vs. standard of care.

BOSTON — A new model forecasted a “substantial clinical burden” of metabolic dysfunction-associated steatotic liver disease in the next 30 years, including twice as many cases of liver cancer and triple the need for liver transplantation.

BOSTON — Food insecurity in adolescents is “very tightly associated” with metabolic dysfunction-associated steatotic liver disease, which may result from not being able to eat or purchase a balanced meal, according to a researcher.

Twelve months of testosterone replacement therapy did not improve metabolic dysfunction-associated steatotic liver disease in a group of older men with hypogonadism, according to a secondary analysis of the T Trials.

DALLAS — New data presented at ObesityWeek demonstrate an encouraging early profile of an investigational dual GLP-1/GIP receptor agonist in healthy adults, according to a speaker at ObesityWeek.

Individuals with low birthweight or born small for gestational age were significantly more likely to develop nonalcoholic fatty liver disease later in life, with additionally higher odds for more severe NAFLD, according to data at UEG Week.

Elevated serum triglyceride levels were associated with severity of acute pancreatitis and risk for related complications, including organ failure, among patients with nonalcoholic fatty liver disease, according to data.